The dividend is just one reason to buy these stocks.There are many reasons to invest in excellent dividend stocks. Such investments are often worth the trouble regardless of whether you're investing for the dividend, or for making capital gains from the robust business (always a laudable goal). But here's the common thread that runs through outstanding dividend stocks: Companies that grow their dividend payouts over extended periods time all have solid fundamentals.The obvious corollary is, not every divide ...

A double beat on the latest quarterly results and raised guidance made investors happy.Scooting past analyst estimates for its latest quarter gave Novartis (NVS 2.27%) a lift on Tuesday. Investors like what they heard about the global healthcare company's inaugural earnings release for 2024, and rewarded Novartis with a more than 2% lift in its stock price today. The shares did better than the S&P 500 index, which had a relatively good trading session with a 1.2% gain.Double beats in the first quarterIn its ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Key TakeawaysNovartis beat first-quarter forecasts for profit and sales on rising demand for its blockbuster drugs.Revenue from the Swiss-based pharmaceutical firm's top-selling medicines, Entresto and Cosentyx, climbed 36% and 25%, respectively.Novartis also boosted its full-year sales and core operating income guidance. American depositary receipts (ADRs) of Novartis (NVS) rose in intraday trading Tuesday as the Swiss-based pharmaceutical firm reported better-than-expected first-quarter results and booste ...

Novartis (NVS) reported $11.83 billion in revenue for the quarter ended March 2024, representing a year-over-year decline of 8.7%. EPS of $1.80 for the same period compares to $1.71 a year ago.The reported revenue represents a surprise of +2.85% over the Zacks Consensus Estimate of $11.5 billion. With the consensus EPS estimate being $1.73, the EPS surprise was +4.05%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expec ...

Swiss pharma giant Novartis AG (NVS) reported better-than-expected results for the first quarter of 2024. Core earnings (excluding one-time charges) of $1.80 per share beat the Zacks Consensus Estimate of $1.73 and were up from $1.54 a year ago. The year-over-year growth was driven by an increase in sales.Revenues of $11.8 billion climbed 10% from the year-ago quarter. On a constant currency basis, sales increased 11%, driven by momentum in Entresto, Kesimpta, Kisqali, Cosentyx, Pluvicto and Leqvio. Sales e ...

Signage for Novartis AG at a building in the company's headquarters campus in Basel, Switzerland, on Monday, Jan. 8, 2023.Shares of Swiss drugmaker Novartis climbed 4.8% in early deals on Tuesday, after the company raised its full-year guidance following better-than-expected first-quarter results.The company said 2024 net sales are now anticipated to pick up by a high-single to low double-digit percentage, up from a previous outlook of mid-single-digit growth. The drugmaker has also revised its expectations ...

Novartis AG (NVS) , a Swiss pharma giant, is scheduled to report first-quarter 2024 results on Apr 23.The company’s earnings surpassed estimates in three of the last four quarters and missed in the remaining one, the average surprise being 3.72%. In the last reported quarter, NVS’ earnings missed estimates by 6.71%.Let's see how things might have shaped up prior to the announcement. Factors Driving GrowthWith the successful spin-off of the Sandoz business in October 2023, Novartis operates as a single globa ...

Analysts on Wall Street project that Novartis (NVS) will announce quarterly earnings of $1.73 per share in its forthcoming report, representing an increase of 1.2% year over year. Revenues are projected to reach $11.5 billion, declining 11.2% from the same quarter last year.The consensus EPS estimate for the quarter has undergone a downward revision of 1.1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates du ...

Novartis (NVS) presented encouraging results from a pre-specified interim analysis of the phase III APPLAUSE-IgAN study of Fabhalta (iptacopan).Fabhalta, an oral, Factor B inhibitor of the alternative complement pathway, is already approved by the FDA for the treatment of adults with the rare blood disorder paroxysmal nocturnal hemoglobinuria.Novartis is looking to expand the drug’s label for the treatment of immunoglobulin A nephropathy (IgAN), a heterogeneous, progressive, rare kidney disease.APPLAUSE-IgA ...